GDC-0853

GDC-0853

CAT N°: 21346
Price:

From 59.00 50.15

GDC-0853 is an inhibitor of Bruton’s tyrosine kinase (BTK; Kis = 0.91, 1.6, 1.3, 12.6, and 3.4 nM for wild-type BTK, BTKC481S, BTKC481R, BTKT474I, and BTKT474M, respectively).{63396} It is selective for BTK over a panel of 287 additional kinases at 1 µM. GDC-0853 inhibits anti-IgM antibody-induced BTK phosphorylation in B cells (IC50 = 3.1 nM), as well as anti-IgM- or CD40L-induced proliferation of B cells (IC50s = 1.2 and 1.4 nM, respectively). In vivo, GDC-0853 (0.06-16 mg/kg) reduces ankle thickness and cartilage damage in a rat model of collagen-induced arthritis.

Territorial Availability: Available through Bertin Technologies only in France

  • Synonyms
    • 2-[1,6-dihydro-3′-(hydroxymethyl)-1-methyl-5-[[5-[(2S)-2-methyl-4-(3-oxetanyl)-1-piperazinyl]-2-pyridinyl]amino]-6-oxo[3,4′-bipyridin]-2′-yl]-3,4,7,8-tetrahydro-7,7-dimethyl-2H-cyclopenta[4,5]pyrrolo[1,2-a]pyrazin-1(6H)-one
  • Correlated keywords
    • GDC0853 RG7845 pBTK RA antiIGM
  • Product Overview:
    GDC-0853 is an inhibitor of Bruton’s tyrosine kinase (BTK; Kis = 0.91, 1.6, 1.3, 12.6, and 3.4 nM for wild-type BTK, BTKC481S, BTKC481R, BTKT474I, and BTKT474M, respectively).{63396} It is selective for BTK over a panel of 287 additional kinases at 1 µM. GDC-0853 inhibits anti-IgM antibody-induced BTK phosphorylation in B cells (IC50 = 3.1 nM), as well as anti-IgM- or CD40L-induced proliferation of B cells (IC50s = 1.2 and 1.4 nM, respectively). In vivo, GDC-0853 (0.06-16 mg/kg) reduces ankle thickness and cartilage damage in a rat model of collagen-induced arthritis.

We also advise you